Safety and tolerability of pirfenidone in asbestosis: a prospective multicenter study.
Anti-fibrotic treatment
Asbestosis
Efficacy
Home monitoring
Pirfenidone
Safety
Journal
Respiratory research
ISSN: 1465-993X
Titre abrégé: Respir Res
Pays: England
ID NLM: 101090633
Informations de publication
Date de publication:
28 May 2022
28 May 2022
Historique:
received:
02
02
2022
accepted:
18
05
2022
entrez:
1
6
2022
pubmed:
2
6
2022
medline:
7
6
2022
Statut:
epublish
Résumé
Pirfenidone slows down disease progression in idiopathic pulmonary fibrosis (IPF). Recent studies suggest a treatment effect in progressive pulmonary fibrosis other than IPF. However, the safety and effectiveness of pirfenidone in asbestosis patients remain unclear. In this study, we aimed to investigate the safety, tolerability and efficacy of pirfenidone in asbestosis patients with a progressive phenotype. This was a multicenter prospective study in asbestosis patients with progressive lung function decline. After a 12-week observational period, patients were treated with pirfenidone 801 mg three times a day. Symptoms and adverse events were evaluated weekly and patients completed online patient-reported outcomes measures. At baseline, start of therapy, 12 and 24 weeks, in hospital measurement of lung function and a 6 min walking test were performed. Additionally, patients performed daily home spirometry measurements. In total, 10 patients were included of whom 6 patients (66.7%) experienced any adverse events during the study period. Most frequently reported adverse events were fatigue, rash, anorexia and cough, which mostly occurred intermittently and were reported as not very bothersome. No significant changes in hospital pulmonary function (forced vital capacity (FVC), diffusion capacity of the lung for carbon monoxide (DLCO), 6 min walking test or patient-reported outcomes measures before and after start of pirfenidone were found. Home spirometry demonstrated a FVC decline in 12 weeks before start of pirfenidone, while FVC did not decline during the 24 week treatment phase, but this difference was not statistically significant. Treatment with pirfenidone in asbestosis has an acceptable safety and tolerability profile and home spirometry data suggest this antifibrotic treatment might attenuate FVC decline in progressive asbestosis. Trial registration MEC-2018-1392; EudraCT number: 2018-001781-41.
Sections du résumé
BACKGROUND
BACKGROUND
Pirfenidone slows down disease progression in idiopathic pulmonary fibrosis (IPF). Recent studies suggest a treatment effect in progressive pulmonary fibrosis other than IPF. However, the safety and effectiveness of pirfenidone in asbestosis patients remain unclear. In this study, we aimed to investigate the safety, tolerability and efficacy of pirfenidone in asbestosis patients with a progressive phenotype.
METHODS
METHODS
This was a multicenter prospective study in asbestosis patients with progressive lung function decline. After a 12-week observational period, patients were treated with pirfenidone 801 mg three times a day. Symptoms and adverse events were evaluated weekly and patients completed online patient-reported outcomes measures. At baseline, start of therapy, 12 and 24 weeks, in hospital measurement of lung function and a 6 min walking test were performed. Additionally, patients performed daily home spirometry measurements.
RESULTS
RESULTS
In total, 10 patients were included of whom 6 patients (66.7%) experienced any adverse events during the study period. Most frequently reported adverse events were fatigue, rash, anorexia and cough, which mostly occurred intermittently and were reported as not very bothersome. No significant changes in hospital pulmonary function (forced vital capacity (FVC), diffusion capacity of the lung for carbon monoxide (DLCO), 6 min walking test or patient-reported outcomes measures before and after start of pirfenidone were found. Home spirometry demonstrated a FVC decline in 12 weeks before start of pirfenidone, while FVC did not decline during the 24 week treatment phase, but this difference was not statistically significant.
CONCLUSIONS
CONCLUSIONS
Treatment with pirfenidone in asbestosis has an acceptable safety and tolerability profile and home spirometry data suggest this antifibrotic treatment might attenuate FVC decline in progressive asbestosis. Trial registration MEC-2018-1392; EudraCT number: 2018-001781-41.
Identifiants
pubmed: 35643466
doi: 10.1186/s12931-022-02061-2
pii: 10.1186/s12931-022-02061-2
pmc: PMC9148498
doi:
Substances chimiques
Pyridones
0
pirfenidone
D7NLD2JX7U
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
139Informations de copyright
© 2022. The Author(s).
Références
Am J Respir Crit Care Med. 2004 Sep 15;170(6):691-715
pubmed: 15355871
Eur Respir J. 2016 Jan;47(1):243-53
pubmed: 26647432
Rheumatology (Oxford). 2021 May 14;60(5):2467-2471
pubmed: 33212511
Lancet Respir Med. 2020 Feb;8(2):147-157
pubmed: 31578169
Eur Respir J. 2017 Jul 5;50(1):
pubmed: 28679608
Lancet Respir Med. 2020 May;8(5):453-460
pubmed: 32145830
Respir Med. 2019 Jul - Aug;154:82-85
pubmed: 31226624
N Engl J Med. 2019 Oct 31;381(18):1718-1727
pubmed: 31566307
Am J Respir Crit Care Med. 2017 Sep 15;196(6):756-761
pubmed: 28471697
ERJ Open Res. 2018 Oct 19;4(4):
pubmed: 30364407
Am J Respir Crit Care Med. 2020 Aug 1;202(3):393-401
pubmed: 32325005
Occup Environ Med. 2020 Dec 15;:
pubmed: 33323453
Occup Environ Med. 2021 Feb 26;:
pubmed: 33637623
Thorax. 2020 Sep;75(9):798-800
pubmed: 32467338
Eur Respir J. 2020 Apr 30;55(4):
pubmed: 31949121
Lancet Respir Med. 2021 May;9(5):476-486
pubmed: 33798455
N Engl J Med. 2020 Sep 3;383(10):958-968
pubmed: 32877584